A Study of Guselkumab in Participants With Active Psoriatic Arthritis

Phase 3 Active, not recruiting NCT04882098

Condition	Arthritis, Psoriatic
Phase	Phase 3
Sponsor	Janssen Research & Development, LLC
Status	Active, not recruiting
Enrollment	1,054 participants
Interventions	Guselkumab
Start date	Jun 17, 2021
Completion date	Dec 30, 2024
Results posted	Feb 4, 2026

Summary

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

At Week 24 · percentage of participants

Group 1: Guselkumab 100 mg q8w	68.3 percentage of participants
Group 2: Guselkumab 100 mg q4w	66.6 percentage of participants
Group 3: Placebo Followed by Guselkumab	47.0 percentage of participants

p-value	<0.001
Difference in percentage	21.3 (95% CI 14.4–28.2)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский